Cevimeline hydrochloride hemihydrate

• CAT Number: I001930
• CAS Number: 153504-70-2
• Molecular Formula: C10H20ClNO2S
• Molecular Weight: 253.79
• Purity: ≥95%
• Synonyms: (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3/’-1-azabicyclo[2.2.2]octane];hydrate;dihydrochloride
• Target: Neuronal Signaling
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: 2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane];hydrate;dihydrochloride
• InChI: InChI=1S/2C10H17NOS.2ClH.H2O/c2*1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11;;;/h2*8-9H,2-7H2,1H3;2*1H;1H2
• InChIKey: ZSTLCHCDLIUXJE-UHFFFAOYSA-N
• SMILES: CC1OC2(CN3CCC2CC3)CS1.CC1OC2(CN3CCC2CC3)CS1.O.Cl.Cl

Cevimeline hydrochloride hemihydrate（Cat No.:I001930）is a medication primarily used to treat dry mouth associated with conditions like Sjögren’s syndrome, a disorder that affects moisture-producing glands. Cevimeline acts as a muscarinic receptor agonist, specifically targeting the M3 receptors in the salivary glands, stimulating saliva production. This helps relieve the discomfort of dry mouth and improves oral health. The hemihydrate form ensures proper hydration and stability of the compound for pharmaceutical use. Cevimeline is typically well-tolerated but may cause side effects like sweating, nausea, or gastrointestinal discomfort in some individuals.

Reference

[1]. Washio, Takuo; Kohsaka, Kazuhiro; Arisawa, Hirohiko; et al.Pharmacokinetics and metabolism of radiolabeled SNI-2011, a novel muscarinic receptor agonist, in healthy volunteers: Comprehensive understanding of absorption, metabolism and excretion using radiolabeled SNI-2011. Arzneimittel-Forschung (2003), 53(2), 80-86.
[2]. Washio, Takuo; Kohsaka, Kazuhiro; Arisawa, Hirohiko; et al.Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs.Arzneimittel-Forschung (2003), 53(1), 26-33.
[3]. Arisawa, Hirohiko; Fukui, Kenji; Imai, Eiichi; et al.General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjogren/’s syndrome. Arzneimittel-Forschung (2002), 52(4), 225-232.
[4]. Iga Y, Arisawa H, Ogane N, Saito Y, Tomizuka T, Nakagawa-Yagi Y, Masunaga H, Yasuda H, Miyata N. (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3/’-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol. 1998 Nov;78(3):373-80.
[5]. Omori Y, Asari T, Maruyama K, Kusama H, Kojima M, Shibata N. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation. Arzneimittelforschung. 2003;53(5):342-50.